Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Autonomix Medical, Inc. (AMIX) on October 30, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC. As of the record date (September 8, 2025), there were 5,941,992 shares of common stock outstanding, with 2,871,639 shares (approximately 48%) voting at the meeting.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
All five proposals submitted to the stockholders were approved. The specific voting outcomes were as follows:
- Proposal 1 (Election of Directors): All five nominees (Walter V. Klemp, Lori Bisson, Jonathan P. Foster, David Robins, Christopher Capelli) were elected. Votes ranged from approximately 1.19 million to 1.24 million "For" each nominee.
- Proposal 2 (Auditor Ratification): Forvis Mazars, LLP was ratified as the independent registered public accounting firm for the year ending March 31, 2026, with 2,609,156 votes "For" and 91,309 "Against".
- Proposal 3 (Reverse Stock Split Authority): Stockholders approved an amendment to the certificate of incorporation granting the Board authority to effect a reverse stock split at a ratio between 1-for-2 and 1-for-25. This received 1,927,998 votes "For" and 370,030 "Against".
- Proposal 4 (Equity Incentive Plan): The amended and restated 2023 Equity Incentive Plan was approved with 1,113,523 votes "For" and 127,874 "Against".
- Proposal 5 (Lincoln Park Capital Fund Issuance): Stockholders approved the issuance of more than 20% of outstanding common stock pursuant to a purchase agreement with Lincoln Park Capital Fund, LLC, to comply with Nasdaq Listing Rule 5635(d). This received 1,184,885 votes "For" and 75,982 "Against".
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard disclosures associated with the proposals. The approval of Proposal 3 indicates a strategic move to potentially adjust the share count to maintain compliance with listing standards or improve marketability, while Proposal 5 confirms a significant capital raise or transaction with Lincoln Park Capital Fund, LLC.
Investor Verification Checklist
- Verify the specific terms and execution timeline of the reverse stock split authorized under Proposal 3.
- Review the definitive purchase agreement with Lincoln Park Capital Fund, LLC referenced in Proposal 5 to understand the dilution impact and capital raised.
- Examine the Definitive Proxy Statement filed on September 12, 2025, for detailed biographies of the elected directors and the full text of the amended Equity Incentive Plan.
- Monitor future filings for the actual implementation of the reverse stock split ratio.